JAKARTA - The state-owned pharmaceutical company PT Indofarma (Persero) Tbk. finally 1.16 billion net profit in 2014 after the previous year net loss of up to Rp54,22 billion.
Based on the company's financial report published on Monday (03/09/2015), stated net sales rose just 3.2% to Rp1.38 trillion from 2013 that reached Rp1,33 trillion.
Gross profit recorded coded INAF reached Rp312,42 billion, lower than the previous year Rp337,56 billion. However, the high burden in 2013 made INAF posted a loss of 32.3 billion, and in 2014 turned into an operating profit Rp46,34 billion.
INAF recorded in earnings in 2014 reached 1.16 billion. In fact, a year before INAF suffer loss for the year amounted to Rp54,22 billion.
To that end, basic earnings per share in 2014 reached Rp0,38 than the previous period recorded a net loss per share Rp17,50.
Meanwhile, the total assets of Indofarma until the end of last year reached Rp1.24 trillion, down slightly from the same period a year earlier Rp1.29 trillion.
The INAF liabilities at December 31, 2014 to reach Rp656,38 billion from the previous Rp703,71 billion. While equity INAF reach Rp591,9 billion from the previous Rp590,7 billion.
Comments
Post a Comment